Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

Not Applicable

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT00310479
• Lead Sponsor: AHS Cancer Control Alberta

Brief Summary

We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.

Detailed Description

The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.

Study Timeline

• Study First Submitted: 2006-04-03
• Study First Submitted QC: 2006-04-03
• Study First Posted: 2006-04-04
• Study Start: 2006-06
• Primary Completion: 2008-03
• Study Completion: 2008-03
• Status Verified: 2012-03
• Last Update Submitted: 2016-02-24
• Last Update Posted: 2016-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 16

Inclusion Criteria

• Histologically verified prostate cancer
• Patient has opted for surgery
• Low risk prostate cancer PSA <1 0, Gleason < 7, Stage < T2b
• No contraindication to MR scanning
• No prior history of malignancy
• Fit for surgery

Exclusion Criteria

• Nonbiopsied lesion
• Intermediate or high risk prostate cancer
• Unfit for surgery
• Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
characteristic metabolic pattern of prostate cancer at 3Tesla

Secondary Outcome Measures

Name	Time	Method
PPV of MRS in the detection of prostate cancer
specificity, accuracy, NPV

Trial Locations

Locations (1)

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada